### 31 OCTOBER 2024

#### EQUITY RESEARCH - COMPANY REPORT

# MEGA LIFESCIENCES

THAILAND / COMMERCE

## **3Q24E hit by baht appreciation**

- Expect a core profit of THB546.6m (-1.8% q-q, +4.0% y-y), hit by the strong Thai baht.
- The outlook for 4Q24 should improve due to seasonality. We maintain our profit estimates for 2024-26 at +5.4% CAGR.
- Maintain BUY rating on cheap valuations.

#### Outlook in 3Q24 is not bright

The outlook for MEGA's 3Q24 performance is not bright due to the Thai baht's relatively rapid appreciation. The average exchange rate in 3Q24 was 34.8 baht/USD, strengthening by 5.2% q-q, but similar to 3Q23. This will lead to a decrease in revenue in baht and an anticipated FX loss of around THB146m. Additionally, the ongoing situation in Myanmar continues to impact consumer product sales in the distribution business.

#### Hit by Thai baht appreciation

We expect the sales revenue in 3Q24 to decrease by 6.9% q-q and 3.2% y-y, reaching THB3.7b. This decline is primarily due to a decrease in its distribution business (44% of total revenue), which is anticipated to fall by 8.1% q-q and 12.1% y-y to THB1.6b, impacted by the depreciation of the kyat and the ongoing decline in the consumer business. However, we expect the revenue from the branded business (55% of total revenue) to remain resilient against economic conditions, although it is somewhat affected by the Thai baht's appreciation during the quarter.

#### Expect core profit to soften q-q but grow y-y

Our expectation of an improved gross margin for the branded business would help offset the decline in the margin of the distribution business, leading to an overall gross margin increase of about 100bps to 46.7%, up from 45.7% in 3Q23, though still lower than in 2Q24, in line with the revenue trends. Additionally, better control of SG&A expenses is expected, resulting in a projected core profit of THB546.6m (-1.8% q-q, +4.0% y-y). However, we estimate the 3Q24 net profit to be at THB455.7m (-11.1% q-q, -14.9% y-y) due to the mentioned FX loss.

#### Maintain our BUY rating on cheap valuations

If our expectations are met, MEGA's core profit for 9M24, which would remain stable y-y, will account for 79% of our full-year estimate of THB2.4b (-9.4% y-y). Meanwhile, the profit outlook for 4Q24 should improve due to seasonality. We maintain our profit estimates for 2024-26, with moderate growth at 5.4% CAGR. We retain our BUY rating on its cheap valuations, with our TP of THB56 (DCF, 8.2% WACC, 3.5% LTG). MEGA's share price trades at only 13.1x 2025E P/E, the lowest among local peers.



**Jitra Amornthum** Fundamental Investment Analyst on Securities; License no. 014530 jitra.a@fssia.com, +66 2646 9966




# **MEGA TB**

# 

TARGET PRICE	THB56.00
CLOSE	THB39.00
UP/DOWNSIDE	+43.6%
PRIOR TP	THB56.00
CHANGE IN TP	UNCHANGED
TP vs CONSENSUS	+20.0%

#### **KEY STOCK DATA**

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	15,681	16,139	16,927	17,736
Net profit	1,993	2,444	2,598	2,715
EPS (THB)	2.29	2.80	2.98	3.11
vs Consensus (%)	-	1.6	(0.7)	(3.4)
EBITDA	3,285	3,201	3,389	3,535
Recurring net profit	2,699	2,444	2,598	2,715
Core EPS (THB)	3.10	2.80	2.98	3.11
Chg. In EPS est. (%	) -	-	-	-
EPS growth (%)	13.4	(9.4)	6.3	4.5
Core P/E (x)	12.6 14.6	13.9	13.1	12.5
Dividend yield (%)	4.1	4.0	4.2	4.4
EV/EBITDA (x)	9.6	9.8	9.2	8.8
Price/book (x)	3.7	3.4	3.3	3.2
Net debt/Equity (%)	(26.4)	(26.3)	(27.5)	(27.7)
ROE (%)	29.9	25.5	25.7	25.8



Sources: Bloomberg consensus; FSSIA estimates

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

#### Investment thesis

The outlook for MEGA's performance in 3Q24 is not bright due to the relatively rapid appreciation of the Thai baht. The average exchange rate in 3Q24 was 34.8 baht/USD, strengthening by 5.2% q-q, but similar to 3Q23. This will lead to a decrease in revenue in baht and an anticipated FX loss of around THB146m. Additionally, the ongoing situation in Myanmar continues to impact consumer product sales in the distribution business.

We project a core profit of THB546.6m (-1.8% q-q, +4.0% y-y). Meanwhile, the profit outlook for 4Q24 should improve due to seasonality. We maintain our profit estimates for 2024-26, with moderate growth at 5.4% CAGR.

#### **Company profile**

MEGA is a leading manufacturer and distributor of pharmaceutical, nutraceutical products and fast-moving consumer goods (FMCG) in developing countries such as Myanmar, Vietnam and Cambodia. MEGA also develops, manufactures, and sells its nutraceutical products, generic prescription pharmaceutical products, and OTC products under Mega We Care brand through its distribution network and third-party distributors in 36 countries across the world.

www.megawecare.com

#### Catalysts

Key potential catalysts include 1) expedited medicine registrations and listings; 2) widespread medical events such as the Covid-19 pandemic; and 3) the success of new products and new markets.

#### Risks to our call


Downside risks to our DCF-based TP include 1) the delayed registration process in many countries; 2) more intensified competition; 3) failure in introducing new products; and 4) risks associated with doing business in Myanmar.

#### Event calendar

Date Event 12 November 2024 3Q24 earnings announcement

#### Principal activities (revenue, 2023)

Mega We Care - 51.0 %




Source: Mega Lifesciences

#### Major shareholders

- Unistretch Co Ltd 49.8 %
- Thai NVDR 8.0 %
- Mr. Vivek Dhawan 5.3 %

Others - 36.9 %



Source: Mega Lifesciences

#### Key assumptions

	(unit)	2024E	2025E	2026E
Mega We Care	(THB m)	8,502	9,097	9,552
Growth	(%)	6.2	7.0	5.0
Gross margin	(%)	64.6	64.6	64.6
Maxxcare	(THB m)	7,319	7,502	7,847
Growth	(%)	(1.0)	2.5	4.6
Gross margin	(%)	23.8	23.4	23.4
SG&A to sales (%)	(%)	27.8	27.8	27.9

Source: FSSIA estimates

#### Earnings sensitivity

- For every 5% change in branded revenue, we project MEGA's 2024 net profit to change by 6%, all else being equal.
- For every 5% change in distribution revenue, we project MEGA's 2024 net profit to change by 1%, all else being equal.
- For every 1% change in overall gross margin, we project MEGA's 2024 net profit to change by 6%, all else being equal.

Source: FSSIA estimates




#### Exhibit 1: MEGA – 3Q24 earnings preview

Year to Dec 31	3Q23	4Q23	1Q24	2Q24	3Q24E	C <u>ha</u>	nge	9M23	9M24E	Change	% of
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)	2024E				
Sales	3,803	4,158	3,733	3,954	3,679	(6.9)	(3.2)	11,523	11,366	(1.4)	70.4
Cost of sales	(2,064)	(2,252)	(1,984)	(2,038)	(1,961)	(3.8)	(5.0)	(6,333)	(5,983)	(5.5)	67.9
Gross profit	1,739	1,905	1,749	1,916	1,719	(10.3)	(1.2)	5,190	5,383	3.7	73.5
Operating costs	(1,021)	(1,104)	(1,066)	(1,140)	(1,034)	(9.3)	1.3	(3,087)	(3,240)	5.0	72.3
Operating profit	718	801	682	776	685	(11.8)	(4.7)	2,103	2,143	1.9	18.2
Operating EBITDA	815	908	775	872	776	(11.0)	(4.8)	2,378	2,423	1.9	75.7
Other income	27	31	22	26	22	(16.2)	(18.2)	64	70	10.4	109.0
Interest expense	(8)	(5)	(5)	(9)	(7)	(24.9)	(16.7)	(27)	(21)	(19.5)	78.8
Profit before tax	737	828	699	793	700	(11.8)	(5.0)	2,140	2,192	2.4	76.2
Тах	(98)	(58)	(71)	(93)	(98)	5.1	0.4	(211)	(262)	24.4	60.7
Reported net profit	536	473	478	513	456	(11.1)	(14.9)	1,519	1,446	(4.8)	59.2
Extraordinaries											
- Net loss from new businesses	11	10	9	0	53			30	62		
- FX los/(gain)	(38)	138	7	(187)	(146)			194	(326)		
- Normalizing tax expense	17	0	0	0	0			(31)	0		
Core profit	526	621	494	557	547	(1.8)	4.0	1,930	1,930	0.0	79.0
Reported EPS (THB)	0.61	0.54	0.55	0.59	0.52	(11.1)	(14.9)	1.74	1.66	(4.8)	59.2
Core EPS (THB)	0.60	0.71	0.57	0.64	0.63	(1.8)	4.0	2.21	2.21	0.0	79.0
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)	
Gross margin	45.7	45.8	46.8	48.5	46.7	(1.7)	1.0	45.0	47.4	2.3	
Operating margin	19.6	20.0	18.9	20.3	19.2	(1.1)	(0.4)	18.3	18.9	0.6	
EBITDA margin	21.4	21.8	20.8	22.1	21.1	(1.0)	(0.3)	20.6	21.3	0.7	
Recurring net margin	13.8	14.9	13.2	14.1	14.9	0.8	1.0	16.7	17.0	0.2	
SG&A / Sales	26.8	26.6	28.6	28.8	28.1	(0.7)	1.3	26.8	28.5	1.7	
Revenue breakdown	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)					
Branded business	1,907	2,126	1,930	2,140	2,008	(6.1)	5.3	5,879	6,079	3.4	
Distribution business	1,825	1,980	1,737	1,746	1,604	(8.1)	(12.1)	5,417	5,087	(6.1)	
OEM business	71	53	65	68	67	(1.9)	(5.2)	227	200	(11.8)	
Gross margin by business unit	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)	
Branded business	65.3	64.3	64.3	66.0	67.0	1.0	1.7	65.2	65.8	0.6	
Distribution business	25.9	26.6	27.9	27.8	22.0	(5.8)	(3.9)	23.7	26.0	2.3	
OEM business	27.9	25.6	34.9	26.1	30.0	3.9	2.1	31.2	30.3	(1.0)	


Sources: MEGA, FSSIA estimates

#### Exhibit 2: Revenue structure




Sources: MEGA, FSSIA estimates

#### Exhibit 3: Revenue from branded business and gross margin




Sources: MEGA, FSSIA estimates



Sources: MEGA, FSSIA estimates





Sources: MEGA, FSSIA estimates

#### Exhibit 8: One-year rolling forward P/E band




Sources: Bloomberg, FSSIA estimates

Exhibit 5: Core profit and margins


#### (%) (THB m) Core profit ----- Gross margin (RHS) \_ EBITDA margin (RHS) Core profit margin (RHS) 60 700 600 50 500 40 400 30 300 20 200 10 100 0 0 3Q24E 1Q19 3Q19 3Q20 3022 3Q23 1Q24 80 022 023 ģ ğ

Sources: MEGA, FSSIA estimates



Sources: MEGA, FSSIA estimates

#### Exhibit 9: One-year rolling forward EV/EBITDA band



Sources: Bloomberg, FSSIA estimates

#### **Financial Statements**

Mega Lifesciences

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	15,686	15,681	16,139	16,927	17,736
Cost of goods sold	(8,647)	(8,586)	(8,816)	(9,206)	(9,640)
Gross profit	7,040	7,095	7,323	7,720	8,097
Other operating income	80	95	65	68	71
Operating costs	(4,359)	(4,191)	(4,483)	(4,706)	(4,948)
Operating EBITDA	3,033	3,285	3,201	3,389	3,535
Depreciation	(272)	(286)	(297)	(307)	(316)
Goodwill amortisation	0	0	0	0	0
Operating EBIT	2,761	2,999	2,904	3,082	3,219
Net financing costs	(29)	(31)	(27)	(25)	(25)
Associates	0	0	0	0	0
Recurring non-operating income	2	0	(1)	(1)	0
Non-recurring items	(138)	(707)	0	0	0
Profit before tax	2,596	2,262	2,876	3,056	3,194
Tax	(355)	(269)	(432)	(459)	(479)
Profit after tax	2,242	1,993	2,444	2,598	2,715
Minority interests	-	-	-	-	-
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	2,242	1,993	2,444	2,598	2,715
Non-recurring items & goodwill (net)	138	707	0	0	0
Recurring net profit	2,380	2,699	2,444	2,598	2,715
Per share (THB)					
Recurring EPS *	2.73	3.10	2.80	2.98	3.11
Reported EPS	2.57	2.29	2.80	2.98	3.11
DPS	1.60	1.60	1.54	1.64	1.71
Diluted shares (used to calculate per share data)	872	872	872	872	872
Growth					
Revenue (%)	11.0	0.0	2.9	4.9	4.8
Operating EBITDA (%)	23.2	8.3	(2.6)	5.9	4.3
Operating EBIT (%)	26.2	8.6	(3.2)	6.1	4.4
Recurring EPS (%)	30.2	13.4	(9.4)	6.3	4.5
Reported EPS (%)	15.1	(11.1)	22.7	6.3	4.5
Operating performance					
Gross margin inc. depreciation (%)	44.9	45.2	45.4	45.6	45.6
Gross margin exc. depreciation (%)	46.6	47.1	47.2	47.4	47.4
Operating EBITDA margin (%)	19.3	21.0	19.8	20.0	19.9
Operating EBIT margin (%)	17.6	19.1	18.0	18.2	18.1
Net margin (%)	15.2	17.2	15.1	15.3	15.3
Effective tax rate (%)	13.7	11.9	15.0	15.0	15.0
Dividend payout on recurring profit (%)	58.6	51.7	55.0	55.0	55.0
Interest cover (X)	96.2	96.0	106.7	121.0	131.2
Inventory days	172.8	164.6	150.0	150.8	150.6
Debtor days	72.0	80.9	82.9	83.0	82.1
Creditor days	163.5	157.6	138.4	135.7	132.9
Operating ROIC (%)	56.8	58.0	47.6	47.3	47.3
ROIC (%)	37.7	39.8	33.6	34.0	34.4
ROE (%)	28.4	29.9	25.5	25.7	25.8
ROA (%)	17.2	19.0	17.1	17.4	17.6
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Mega We Care	8,053	8,005	8,502	9,097	9,552
Maxxcare	7,320	7,397	7,319	7,502	7,847
OEM	314	280	317	327	337

Sources: Mega Lifesciences; FSSIA estimates

## **FINANSIA**

#### **Financial Statements**

Mega Lifesciences

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	2,380	2,699	2,444	2,598	2,715
epreciation	272	286	297	307	316
ssociates & minorities	0	0	0	0	(
ther non-cash items	474	671	(47)	(244)	(335
hange in working capital	(989)	(1,023)	(845)	(663)	(723
ash flow from operations	2,136	2,633	1,850	1,998	1,973
apex - maintenance	-	-	-	-	
apex - new investment	(305)	(294)	(330)	(300)	(340
let acquisitions & disposals	-	-	-	-	
Other investments (net)	24	44	0	0	(
Cash flow from investing	(281)	(250)	(330)	(300)	(340)
lividends paid	(1,406)	(1,439)	(1,344)	(1,429)	(1,493)
quity finance	0	0	0	0	0
Debt finance	2	(237)	(9)	23	(5)
Other financing cash flows	(30)	(32)	(27)	(25)	(25
ash flow from financing	(1,433)	(1,708)	(1,380)	(1,431)	(1,523)
lon-recurring cash flows	-	-	-	-	
Other adjustments	0	0	0	0	(
et other adjustments	(165)	(751)	0	0	(
lovement in cash	257	(76)	139	267	110
ree cash flow to firm (FCFF)	1,884.18	2,414.24	1,546.77	1,723.07	1,657.35
ree cash flow to equity (FCFE)	1,662.78	1,362.98	1,483.56	1,695.36	1,603.49
er share (THB)					
CFF per share	2.16	2.77	1.77	1.98	1.90
CFE per share	1.91	1.56	1.70	1.94	1.84
ecurring cash flow per share	3.58	4.19	3.09	3.05	3.09
alance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
angible fixed assets (gross)	4,062	4,309	4,639	4,939	5,279
ess: Accumulated depreciation	(2,161)	(2,334)	(2,631)	(2,938)	(3,254
angible fixed assets (net)	1,901	1,974	2,008	2,001	2,025
ntangible fixed assets (net)	1,329	1,318	1,344	1,353	1,343
ong-term financial assets	0	0	0	0	, (
vest. in associates & subsidiaries	223	221	221	221	221
ash & equivalents	2,789	2,712	2,851	3,118	3,228
/C receivable	3,382	3,570	3,758	3,942	4,033
iventories	4,109	3,377	3,623	3,733	3,962
ther current assets	310	330	345	333	344
Current assets	10,590	9,990	10,578	11,126	11,567
Other assets	603	611	592	593	594
otal assets	14,646	14,115	14,743	15,294	15,750
Common equity	8,777	9,302	9,902	10,351	10,723
/inorities etc.	0	0	0	0	(
otal shareholders' equity	8,777	9,302	9,902	10,351	10,723
ong term debt	109	132	125	151	148
Other long-term liabilities	223	244	299	313	328
ong-term liabilities	332	376	424	464	476
/C payable	3,972	3,197	3,261	3,355	3,433
hort term debt	312	120	118	116	114
Other current liabilities	1,254	1,119	1,039	1,009	1,004
current liabilities	5,538	4,437	4,417	4,479	4,551
otal liabilities and shareholders' equity	14,646	14,115	14,743	15,294	15,750
et working capital	2,575	2,961	3,428	3,645	3,902
nvested capital Includes convertibles and preferred stock which is be	6,632	7,086	7,592	7,813	8,085
includes convertibles and preferred stock which is be	ing treated as dept				
er share (THB)					
ook value per share	10.07	10.67	11.36	11.87	12.30
angible book value per share	8.54	9.16	9.82	10.32	10.76
inancial strength					
et debt/equity (%)	(27.0)	(26.4)	(26.3)	(27.5)	(27.7
let debt/total assets (%)	(16.2)	(17.4)	(17.7)	(18.6)	(18.8
urrent ratio (x)	1.9	2.3	2.4	2.5	2.5
F interest cover (x)	69.5	54.0	67.6	79.4	80.2
aluation	2022	2023	2024E	2025E	20265
ecurring P/E (x) *	14.3	12.6	13.9	13.1	12.
ecurring P/E @ target price (x) *	20.5	18.1	20.0	18.8	18.0
eported P/E (x)	15.2	17.1	13.9	13.1	12.5
ividend yield (%)	4.1	4.1	4.0	4.2	4.4
rice/book (x)	3.9	3.7	3.4	3.3	3.2
rice/tangible book (x)	4.6	4.3	4.0	3.8	3.6
V/EBITDA (x) **	10.4	9.6	9.8	9.2	8.8
V/EBITDA @ target price (x) **	15.3	14.1	14.4	13.6	13.0
V/invested capital (x)	4.8	4.5	4.1	4.0	3.8

Sources: Mega Lifesciences; FSSIA estimates



# **MEGA LIFESCIENCES PCL (MEGA TB)**

**FSSIA ESG rating** 

 $\star \star \star$ 

54.48 /100

#### Exhibit 10: FSSIA ESG score implication

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
$\star \star \star \star$	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Source: FSSIA estimates

#### Exhibit 11: ESG – peer comparison

	FSSIA			Dome	stic ratings			Global ratings						Bloomberg		
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score	
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17	
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94	
COM7	61.78		Y	Y	5.00	5.00	Certified	Low	47.75			52.68	21.00	4.40	43.59	
MEGA	54.48		Y	Y	4.00	4.00	Declared	Medium	66.56			58.59	24.00	2.39		
BJC	71.33	Y	Y	Y	4.00	4.00		Medium	55.09	Α		65.19	89.00	2.16		
CRC	64.49		Y	Y	5.00	5.00	Certified	Medium		BBB		60.98	73.00	2.90	47.27	

Sources: SETTRADE.com; FSSIA's compilation

#### Exhibit 12: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	2.29	-
BESG environmental pillar score	_	1.86	—
BESG social pillar score	_	1.06	_
BESG governance pillar score	_	4.54	_
ESG disclosure score	44.34	53.36	—
Environmental disclosure score	29.84	44.22	—
Social disclosure score	19.44	32.16	—
Governance disclosure score	83.59	83.59	—
Environmental			
Emissions reduction initiatives	Yes	Yes	Yes
Climate change policy	Yes	Yes	No
Climate change opportunities discussed	No	No	No
Risks of climate change discussed	No	No	No
GHG scope 1	_	_	633
GHG scope 2 location-based	_	_	6
GHG Scope 3	_	—	0
Carbon per unit of production	_	_	_
Biodiversity policy	No	No	No
Energy efficiency policy	Yes	Yes	Yes
Total energy consumption	24	24	23
Renewable energy use	1	1	1
Electricity used	12	13	12
Fuel used - natural gas	_	_	914

Sources: Bloomberg; FSSIA's compilation

#### Exhibit 13: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No
Waste reduction policy	Yes	Yes	Yes
Hazardous waste	—	—	0
Total waste	1	1	1
Waste recycled	0	0	—
Waste sent to landfills	_	—	—
Environmental supply chain management	Yes	Yes	No
Water policy	No	Yes	Yes
Water consumption	—	—	0
Social			
Human rights policy	Yes	Yes	Yes
Policy against child labor	Yes	Yes	Yes
Quality assurance and recall policy	No	Yes	Yes
Consumer data protection policy	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes
Gender pay gap breakout	No	No	No
Pct women in workforce	56	56	56
Pct disabled in workforce	_	_	_
Business ethics policy	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes
Health and safety policy	Yes	Yes	No
Lost time incident rate - employees	0	0	_
Total recordable incident rate - employees	_	_	_
Training policy	Yes	Yes	Yes
Fair remuneration policy	No	No	No
Number of employees – CSR	5,714	6,021	5,767
Employee turnover pct	_	19	
Total hours spent by firm - employee training	70,551	79,892	70,826
Social supply chain management	Yes	Yes	Yes
Governance			
Board size	10	10	10
No. of independent directors (ID)	4	4	4
No. of women on board	1	1	1
No. of non-executive directors on board	8	8	8
Company conducts board evaluations	Yes	Yes	Yes
No. of board meetings for the year	6	5	7
Board meeting attendance pct	100	96	94
Board duration (years)	3	3	3
Director share ownership guidelines	No	No	No
Age of the youngest director	32	33	34
Age of the oldest director	80	81	82
No. of executives / company managers	6	6	6
No. of female executives	1	1	1
Executive share ownership guidelines	No	No	No
Size of audit committee	3	3	3
No. of ID on audit committee	3	3	3
	4	4	4
Audit committee meetings Audit meeting attendance %	4 100	4 100	4 100
	3	3	3
Size of compensation committee			
No. of ID on compensation committee	1	1	1
	2	2	2
No. of compensation committee meetings		100	100
Compensation meeting attendance %	100	•	•
Compensation meeting attendance % Size of nomination committee	3	3	
Compensation meeting attendance % Size of nomination committee No. of nomination committee meetings	<b>3</b> 2	2	<b>3</b> 3
Compensation meeting attendance % Size of nomination committee	3		

Sources: Bloomberg; FSSIA's compilation

## **FINANSIA**

#### **Disclaimer for ESG scoring**

ESG score	Methodolog	I <u>y</u>			Rating							
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the ann Only the top- inclusion.	ed on the com ual S&P Glob -ranked comp	transparent, rules-based npanies' Total Sustainabi al Corporate Sustainabili anies within each industr	lity Scores resulting ity Assessment (CSA). y are selected for	scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.							
Sustainability Investment List ( <u>THSI</u> ) by The Stock Exchange of Thailand ( <u>SET</u> )	managing bu Candidates r 1) no irregula float of >150 up capital. S 70%; 2) inde wrongdoing r	usiness with tr must pass the ar trading of th shareholders ome key disquered pendent direct related to CG	ility in Environmental and ansparency in Governan preemptive criteria, with he board members and e s, and combined holding r ualifying criteria include: ctors and free float violati social & environmental aarnings in red for > 3 yea	ace, updated annually. two crucial conditions: executives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJS during the assessment year. The scoring will be fairly weighted against in nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight maximum, and no cap for number of stocks.							
<b>CG Score</b> by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	he Thai IOD,	h in sustainable developi with support from the Sto ts are from the perspectiv s.	ock Exchange of	Good (80-89), and not rated for equitable treatr	B for Good (70 or scores belo nent of shareh (5%); 4) disclo	ories: 5 for Excel 1-79), 2 for Fair (f 1-80, Weightings 10Iders (weight 2 10 sure & transpare	60-69), 1 for P include: 1) th 5% combined	ass (60-69), le rights; 2) an ); 3) the role o			
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the criteria cover date (45%), a circulation of s exercised. The and verifiability	e incorporated and sufficientl e CG compon r AGM proced and after the i ufficient informa s second assess r; and 3) openne	which shareholders' rights d into business operation y disclosed. All form impu- tents to be evaluated anr lures before the meeting meeting (10%). (The first a tion for voting; and 2) facilitat ses 1) the ease of attending in ses for Q&A. The third involve es, resolutions and voting re-	s and information is ortant elements of two nually. The assessment (45%), at the meeting ssesses 1) advance ting how voting rights can be neetings; 2) transparency as the meeting minutes that	be							
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmer policies. The (Companies de Declaration of Certification, in managers and	nt of key contr Certification eciding to becon Intent to kick off ocluding risk ass	Checklist include corrupti rols, and the monitoring a is good for three years. If an 18-month deadline to sul ressment, in place of policy a rablishment of whistleblowing II stakeholders.)	and developing of start by submitting a bmit the CAC Checklist for nd control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.							
<u>Morningstar</u> Sustainalytics	based on an risk is unmar regulatory filing	assessment of naged. Sources	sk rating provides an ove of how much of a compa s to be reviewed include corp her media, NGO reports/web	ny's exposure to ESG porate publications and sites, multi-sector			score is the sum higher ESG risk Medium		ed risk. The Severe			
		uality & peer rev	k, ESG controversies, issuer iews.	0-10	10-20	20-30	30-40	40+				
<u>ESG Book</u>	positioned to the principle helps explair over-weightir	outperform o of financial m n future risk-a	sustainable companies the over the long term. The materiality including inform djusted performance. Ma ith higher materiality and arly basis.	nethodology considers nation that significantly nteriality is applied by	scores using m	ateriality-base	ated as a weight d weights. The s idicating better p	core is scaled				
MSCI				anagement of financially their exposure to ESG ri					nethodology to			
	AAA AA	8.571-10.00 7.143-8.570	Leader:	leading its industry in m	managing the most significant ESG risks and opportunities							
	A BBB BB	5.714-7.142 4.286-5.713 2.857-4.285	3 Average:	a mixed or unexception industry peers								
	B CCC	1.429-2.856 0.000-1.428	Laggard:	lagging its industry base	ed on its high exposure and failure to manage significant ESG risks							
Moody's ESG solutions	believes that	a company ir		take into account ESG o to its business model an medium to long term.								
Refinitiv ESG rating	based on pu	blicly available	e and auditable data. The	a company's relative ES e score ranges from 0 to are 0 to 25 = poor; >25 to 50	100 on relative E	SG performar	ice and insufficie	nt degree of t				
S&P Global							of ESG risks, op	portunities, ar	id impacts			
Bloomberg	ESG Score		ESG Disclosure Score Score Disclosure of a company's ESG used for Bloomberg ESG score. The score ranges from 0 for none to 100 for disclosure of									

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings. Source: FSSIA's compilation

## **FINANSIA**

#### GENERAL DISCLAIMER

#### ANALYST(S) CERTIFICATION

#### Jitra Amornthum FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

#### History of change in investment rating and/or target price



Jitra Amornthum started covering this stock from 20-Feb-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Mega Lifesciences	MEGA TB	THB 39.00	BUY	Downside risks to our DCF-based TP include 1) the delayed registration process in many countries; 2) more intensified competition; 3) failure in introducing new products; and 4) risks associated with doing business in Myanmar.

Source: FSSIA estimates

#### **Additional Disclosures**

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 30-Oct-2024 unless otherwise stated.

#### **RECOMMENDATION STRUCTURE**

#### **Stock ratings**

Stock ratings are based on absolute upside or downside, which we define as (target price\* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

#### **Industry Recommendations**

**Overweight.** The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

#### **Country (Strategy) Recommendations**

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

